Crestline Management’s Myriad Genetics MYGN Stock Holding History

Crestline Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-22,000	Closed	-$611K	–	98
2019 Q2	$611K	Buy	+22,000	New	+$621K	0.08%	68

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Crestline Management's MYGN Position: Q3 2019 in Review

Crestline Management sold out of Myriad Genetics (MYGN) in Q3 2019, closing a stake of 22,000 shares — an estimated $611K sold.

Crestline Management first reported a position in MYGN in Q2 2019 and held it in 1 quarter. The position peaked at $611K in Q2 2019. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

Crestline Management reported no remaining Myriad Genetics position as of Q3 2019 after selling out during the quarter.
Crestline Management sold 22,000 Myriad Genetics shares in Q3 2019, an estimated $611K.
Crestline Management first reported a position in Myriad Genetics in Q2 2019 and held it in 1 quarter.
Crestline Management's Myriad Genetics position peaked at $611K in Q2 2019.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on Crestline Management's 13F filing for Q3 2019, filed 13 Nov 2019.